Merck (MRK) stock is in focus as a Phase 3 trial for its cancer drug Keytruda in colorectal cancer patients did not meet ...

Merck said on Wednesday a combination of its experimental drug and blockbuster therapy Keytruda failed a late-stage trial ...

An attempt by Merck & Co. to unlock the microsatellite stable (MSS) metastatic colorectal cancer market has ended in failure.

Merck & Co.’s stock was flat on Wednesday, after the drug company said a late-stage trial of its blockbuster cancer drug Keytruda in combination with favezelimab failed to meet the main goal of ...

Merck & Co/MSD has won approval in the US for PD-1 inhibitor Keytruda as a treatment for hepatocellular carcinoma (HCC), the most common form of liver cancer, opening up another front in its ...

Merck & Co.’s stock fell 0.5% premarket Wednesday, after the drug company said a late-stage trial of its blockbuster cancer drug Keytruda in combination with favezelimab failed to meet the main goal ...

For patients with newly diagnosed high-risk endometrial cancer, postsurgical Keytruda (pembrolizumab) and chemotherapy with or without radiation ... the lung tissue), thyroiditis (inflammation of the ...

Merck’s cancer immunotherapy Keytruda is the drug industry’s biggest blockbuster, bringing in $25 billion in sales last year. For years drug companies have sought to beat the therapy to no avail.

Keytruda (pembrolizumab) is an immunotherapy drug used to treat many types of cancer. Your doctor will use imaging, blood tests, and other laboratory tests to monitor whether the drug is working.

SAN DIEGO — For years, Merck’s drug Keytruda has dominated cancer immunotherapy, racking up dozens of approvals, extending the lives of patients, and bringing in billions of dollars to the ...

Patients with previously untreated, high-risk locally advanced cervical cancer experienced improved survival when treated with Keytruda plus chemoradiotherapy ... 4.2% versus 3.8%), colitis ...